HER2 Amplification Shows Prognostic Capabilities in mCRC : c

HER2 amplification appears to be prognostic in patients with RAS wild-type metastatic colorectal cancer but may not be predictive of survival benefit as a first-line treatment option in combination with panitumumab vs standard-of-care bevacizumab.

Related Keywords

, Panitumumab Vs Bevacizumab , Patients With Ras Wild Type Metastatic Colorectal Cancer , Paradigm Trial , Nct02394795 ,